Dry eye disease is a multifactorial condition of the ocular surface characterised by tear film instability and hyperosmolarity, affecting an estimated 15–30% of adults. Management spans artificial tear supplementation to anti-inflammatory topical therapies including cyclosporine and lifitegrast. Emerging approaches targeting neuroinflammation, goblet cell restoration, and novel lubricant formulations are advancing through development.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Ocular Allergy Treatment May Require Multi-Specialty Collaboration
Effective management of ocular allergy, particularly severe or refractory cases, often necessitates collaboration between ophthalmologists and allergy/asthma specialists.
Ocular Allergy Rates Rise, Prompting Collaborative Eco-Conscious Interventions
Rising ocular allergy prevalence necessitates integrated clinical and environmental strategies to mitigate disease burden and improve patient outcomes.